Kamran A. Ahmed, MD

home / authors / kamran-a.-ahmed,-md

Articles

Kamran A. Ahmed, MD, of Moffitt Cancer Center

Dr. Ahmed on the Need for Multidisciplinary Care in HER2+ Breast Leptomeningeal Disease

Kamran A. Ahmed, MD
June 29th 2021

Kamran A. Ahmed, MD, discusses the need for multidisciplinary care in patients with HER2-positive breast cancer and leptomeningeal disease.

Read More

Dr. Ahmed on the Impact of Neratinib on CNS Metastases in HER2+ Breast Cancer

Dr. Ahmed on the Impact of Neratinib on CNS Metastases in HER2+ Breast Cancer

Kamran A. Ahmed, MD
September 3rd 2020

Kamran A. Ahmed, MD, discusses the impact of neratinib on patients with central nervous system metastases and HER2-positive breast cancer.

Read More

Dr. Ahmed on the Role of Multidisciplinary Care in Breast Cancer Brain Metastases

Dr. Ahmed on the Role of Multidisciplinary Care in Breast Cancer Brain Metastases

Kamran A. Ahmed, MD
August 10th 2020

Kamran A. Ahmed, MD, discusses the role of multidisciplinary care in breast cancer–related brain metastases.

Read More

Dr. Ahmed on Remaining Questions With Tucatinib in Breast Cancer Brain Metastases

Dr. Ahmed on Remaining Questions With Tucatinib in Breast Cancer Brain Metastases

Kamran A. Ahmed, MD
August 6th 2020

Kamran A. Ahmed, MD, discusses remaining questions with the use of tucatinib in breast cancer–related brain metastases.

Read More

Dr. Ahmed on Key Strategies for Managing Breast Cancer Brain Metastases

Dr. Ahmed on Key Strategies for Managing Breast Cancer Brain Metastases

Kamran A. Ahmed, MD
July 15th 2020

Kamran A. Ahmed, MD, discusses key strategies to manage patients with breast cancer and brain metastases.

Read More

Latest Updated Articles

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 3rd 2024
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC